OBJECTIVES: Activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are the most common and frequent changes observed in pancreatic cancer. This study aimed to determine the frequency and extent of intratumoral and metastatic lymph node KRAS mutation heterogeneity of resected pancreatic ductal adenocarcinoma. METHODS: Tumor tissues macrodissected from tumor centers, invasion fronts (n = 97), and lymph nodes (n = 11) were subjected to DNA extraction and mutation analysis of KRAS codons 12 and 13 by pyrosequencing. RESULTS: Activating mutations in codon 12 of KRAS were detected in 90 (92.8%) tumor centers. No mutations were detected in KRAS codon 13 in any patient. After a comparison of tumor centers and invasion fronts, intratumoral heterogeneity of KRAS was observed only in 4 (4.1%) cases. Additional invasion front tumor analysis revealed the same mutation status consistent with each tumor center. No heterogeneity was observed between primary tumors and metastatic lymph nodes. CONCLUSIONS: Intratumoral heterogeneity of the KRAS mutational status is rare in pancreatic ductal adenocarcinoma. In addition, no KRAS heterogeneity between primary tumors and metastatic lymph nodes was detected in this study. This finding is consistent with the hypothesis that oncogenic activation of KRAS is the first driver mutation in pancreatic cancer.
OBJECTIVES: Activating Kirsten ratsarcoma viral oncogene homolog (KRAS) mutations are the most common and frequent changes observed in pancreatic cancer. This study aimed to determine the frequency and extent of intratumoral and metastatic lymph node KRAS mutation heterogeneity of resected pancreatic ductal adenocarcinoma. METHODS:Tumor tissues macrodissected from tumor centers, invasion fronts (n = 97), and lymph nodes (n = 11) were subjected to DNA extraction and mutation analysis of KRAS codons 12 and 13 by pyrosequencing. RESULTS: Activating mutations in codon 12 of KRAS were detected in 90 (92.8%) tumor centers. No mutations were detected in KRAS codon 13 in any patient. After a comparison of tumor centers and invasion fronts, intratumoral heterogeneity of KRAS was observed only in 4 (4.1%) cases. Additional invasion front tumor analysis revealed the same mutation status consistent with each tumor center. No heterogeneity was observed between primary tumors and metastatic lymph nodes. CONCLUSIONS: Intratumoral heterogeneity of the KRAS mutational status is rare in pancreatic ductal adenocarcinoma. In addition, no KRAS heterogeneity between primary tumors and metastatic lymph nodes was detected in this study. This finding is consistent with the hypothesis that oncogenic activation of KRAS is the first driver mutation in pancreatic cancer.
Authors: Jami L Saloman; Kathryn M Albers; Zobeida Cruz-Monserrate; Brian M Davis; Mouad Edderkaoui; Guido Eibl; Ariel Y Epouhe; Jeremy Y Gedeon; Fred S Gorelick; Paul J Grippo; Guy E Groblewski; Sohail Z Husain; Keane K Y Lai; Stephen J Pandol; Aliye Uc; Li Wen; David C Whitcomb Journal: Pancreas Date: 2019-07 Impact factor: 3.327
Authors: Thomas G Cotter; Kelli N Burger; Mary E Devens; Julie A Simonson; Kari L Lowrie; Russell I Heigh; Douglas W Mahoney; David H Johnson; David A Ahlquist; John B Kisiel Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-20 Impact factor: 4.254
Authors: Philip A Philip; Ibrahim Azar; Joanne Xiu; Michael J Hall; Andrew Eugene Hendifar; Emil Lou; Jimmy J Hwang; Jun Gong; Rebecca Feldman; Michelle Ellis; Phil Stafford; David Spetzler; Moh'd M Khushman; Davendra Sohal; A Craig Lockhart; Benjamin A Weinberg; Wafik S El-Deiry; John Marshall; Anthony F Shields; W Michael Korn Journal: Clin Cancer Res Date: 2022-06-13 Impact factor: 13.801
Authors: Alexandria Turner; Danielle R Bond; Quan V Vuong; Anita Chalmers; Emma L Beckett; Judith Weidenhofer; Christopher J Scarlett Journal: Mol Biol Rep Date: 2020-02-17 Impact factor: 2.316
Authors: Vincent L Cannataro; Stephen G Gaffney; Carly Stender; Zi-Ming Zhao; Mark Philips; Andrew E Greenstein; Jeffrey P Townsend Journal: Oncogene Date: 2018-02-16 Impact factor: 9.867